Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pulsed-Field Ablation vs. Radiofrequency Ablation CombIned With Vein of Marshall Ethanol Ablation on Mitral Isthmus Block and Clinical Outcomes in Persistent Atrial Fibrillation: The PRIME-AF Randomized Clinical Trial

NCT06866704 is registered in ClinicalTrials.gov with lingzhiyu as lead sponsor.

NCT NCT06866704
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06866704 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pulsed-Field Ablation vs. Radiofrequency Ablation CombIned With Vein of Marshall Ethanol Ablation on Mitral Isthmus Block and Clinical Outcomes in Persistent Atrial Fibrillation: The PRIME-AF Randomized Clinical Trial
Lead sponsor
lingzhiyu
Phase
Not applicable
Overall status
Not yet recruiting
Start date
April 1, 2025
Completion date
December 31, 2026
Enrollment
154 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

atrial fibrillation (af)